Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer.

AUTOR(ES)

Merigan, T C

RESUMO

Because of encouraging results when human leukocyte interferon was given for 5 to 7 days to treat early localized herpes zoster in patients with cancer, a small placebo-controlled, randomized, double-blind trial was set up involving only 48 h of therapy. In this trial, there was no effect on acute pain or disease progression in the primary dermatome. However, a modest but significant effect was noted in that distal cutaneous spread was diminished in the treated patients compared with the controls and the treated patients had diminished severity and duration of postherpetic neuralgia. No evidence of impairment in varicella-zoster-specific lymphocyte transformation was observed in interferon-treated patients.

Documentos Relacionados

• Short-Course Artesunate Treatment of Uncomplicated Plasmodium falciparum Malaria in Gabon
• Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever.
• Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection
• Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis.
• Short-course isoniazid plus rifapentine therapy for latent tuberculosis in Brazil